Sonoma Pharmaceuticals, Inc. specializes in developing and commercializing innovative topical prescription products for dermatological conditions, leveraging its proprietary technology platform. The company primarily operates in the U.S. and Europe, focusing on markets with high unmet medical needs, such as wound care and dermatology.
Business Overview
Sonoma Pharmaceuticals generates revenue through the sale of prescription products that utilize its patented technology for enhanced drug delivery. The company maintains pricing power due to its unique formulations and the regulatory barriers associated with drug approvals.
Regulatory approvals for new products
Partnerships with larger pharmaceutical companies
Market adoption rates of existing products
Changes in reimbursement policies for dermatological treatments
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in drug delivery systems
Increased competition from generic drug manufacturers
Emergence of new treatment modalities in dermatology
Negative operating cash flow could limit operational flexibility
High net loss margins impacting investor confidence
Macro Sensitivity
moderate - The demand for healthcare products is somewhat insulated from economic downturns, but overall spending on healthcare can be affected by GDP growth.
Interest rates impact the company's cost of capital for financing operations and R&D. Higher rates could constrain growth by increasing financing costs.
minimal - Sonoma Pharmaceuticals has a manageable debt-to-equity ratio of 0.27, indicating low reliance on external credit.
Profile
growth - Investors seeking exposure to innovative healthcare solutions and potential high returns from successful product launches.
high - The stock has demonstrated significant volatility, evidenced by a 1-year return of -60.7%.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
